Huashen Technology disclosed its earnings forecast, expecting a net profit attributable to the parent company of 4.8 million to 7.1 million yuan for the first half of 2026, compared with a loss of 54.844 million yuan in the same period last year, achieving a year-on-year turnaround. Deducted non-recurring net profit is expected to be 4.4 million to 6.5 million yuan, compared with a loss of 54.6253 million yuan in the same period last year. Basic earnings per share are expected to be between 0.0077 yuan and 0.0114 yuan. The company stated that the change in performance is mainly due to its continued focus on the core pharmaceutical business, in-depth exploration of the clinical value of products, active expansion of incremental markets outside hospitals, and simultaneous dynamic optimization of resources and expense investment, improvement of the cost control system, and enhancement of market operation efficiency and business quality.
Chengdu Huasun Group Inc LtdExpects first-half 2026 profit turnaround from loss, driven by cost control and market expansion.